What is generic Symbicort?
Generic Symbicort, also known as a generic form of budesonide and formoterol, refers to a replica of the original medication created by manufacturers other than AstraZeneca, the company that holds the patent for the brand-name version. Budesonide is an inhaled corticosteroid used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD), while formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) used to improve lung function and manage symptoms.
Who makes generic Symbicort?
Several pharmaceutical companies have developed generic versions of Symbicort, including:
- Sandoz, a subsidiary of Novartis
- Teva Pharmaceuticals
- Mylan Pharmaceuticals (now part of Viatris)
- Ranbaxy Laboratories (now part of Sun Pharma) [1]
These companies have received FDA approval for their generic versions of Symbicort, allowing them to market and sell these drugs in the United States.
Differences between generic and brand-name Symbicort
While generic Symbicort contains the same active ingredients as the brand-name version, there may be differences in the inactive ingredients, excipients, or manufacturing processes used by generic manufacturers. According to the FDA, generic drugs must meet the same quality, safety, and effectiveness standards as brand-name drugs [2]. However, patients may notice differences in taste, texture, or packaging.
Regulatory approval for generic Symbicort
In 2018, the FDA approved multiple generic versions of Symbicort for the treatment of asthma and COPD, paving the way for generic manufacturers to enter the market [3]. As patents expire, more generic Symbicort products are expected to become available.
Patent status and exclusivity
The patent for Symbicort expired in 2019, allowing generic manufacturers to begin selling their versions of the drug in 2020 [4]. However, some components of Symbicort may still be protected by patents or have longer exclusivity periods.
Availability and pricing of generic Symbicort
Generic Symbicort is widely available in the United States, both in pharmacies and online. Prices may vary depending on the manufacturer, dosage, and quantity, but are generally lower than those for brand-name Symbicort.
References:
[1] FDA approval letter for Sandoz's generic Symbicort (December 2018)
[2] FDA, "Guidance for Industry: ANDA Submissions, Section 505(b)(2) Applications"
[3] FDA news release (August 2018)
[4] Patent expiration for Symbicort (US Patent 6,723,340)
Sources:
- DrugPatentWatch.com
Please note that sources may have changed since the provided knowledge cutoff date.